Pharmaron Beijing Co (STU:17Q1) 3-Year Revenue Growth Rate : 31.20% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pharmaron Beijing Co 3-Year Revenue Growth Rate?

Pharmaron Beijing Co's Revenue per Share for the three months ended in Mar. 2024 was €0.19.

During the past 12 months, Pharmaron Beijing Co's average Revenue per Share Growth Rate was 19.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 31.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 26.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 10 years, the highest 3-Year average Revenue per Share Growth Rate of Pharmaron Beijing Co was 31.80% per year. The lowest was 18.70% per year. And the median was 23.20% per year.

Competitive Comparison of Pharmaron Beijing Co's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Pharmaron Beijing Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmaron Beijing Co's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's 3-Year Revenue Growth Rate falls into.

Pharmaron Beijing Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Pharmaron Beijing Co (STU:17Q1) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Pharmaron Beijing Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co (STU:17Q1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (STU:17Q1) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

PHBBF:USA 03759:Hong Kong 300759:China

Address

No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG

Website

https://www.pharmaron.com

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.

Pharmaron Beijing Co (STU:17Q1) Headlines

No Headlines